The third quarter report of the science and technology innovation board came, and the companys net profit increased by more than 130 times compared with the same period of last year

category:Finance
 The third quarter report of the science and technology innovation board came, and the companys net profit increased by more than 130 times compared with the same period of last year


Shengxiang biology: the king of the performance increase of science and Technology Innovation Board

Among the 24 listed companies listed on the science and technology innovation board, 6 companies expect their revenue to decline year-on-year in the first three quarters, 14 companies expect their revenue to increase year-on-year, and another four companies expect their revenue to fall in the range of year-on-year decline and year-on-year growth.

Among them, Shengxiang biology has handed over the third quarter performance answer sheet, which can be said to be a unique branch.

Shengxiang bio mentioned in the prospectus that it is expected to achieve 2.996 billion yuan of operating revenue from January to September 2020, an increase of 1131.11% compared with the same period of last year; it is estimated that the net profit attributable to the parent after deducting non recurring profit and loss from January to September 2020 will be 1.729 billion yuan, with an increase of 13457.15% compared with the same period of last year, and its performance will grow rapidly.

In 2020, the products produced and sold by Shengxiang bio are mainly new coronavirus nucleic acid detection related products. From April to June this year, the sales revenue of Shengxiang biological new coronavirus detection reagent to the third-party detection center accounted for 44.61% of the domestic sales. Since then, with the domestic epidemic situation gradually controlled, the focus of Shengxiang biological new coronavirus detection reagent began to shift to the international market. In April, may and June this year, the companys overseas sales accounted for 56.28%, 51.30% and 67.28% respectively.

However, Shengxiang biological also said that the substantial growth of its performance after the reporting period is accidental, and there is a risk of unsustainable and large fluctuations in future performance.

Double edged sword of epidemic situation

The company said that the sales of the products mentioned above will continue to improve and there is still room for growth. Xinhai Technology is expected to achieve a business income of 250 million yuan to 280 million yuan from January to September this year, with a year-on-year increase of 64.45% - 84.19%, and a net profit of 63 million yuan to 68 million yuan, a year-on-year increase of 142.95% - 162.23%.

At the same time, more companies were affected by the new crown epidemic, resulting in weak performance in the third quarter.

In addition, due to the impact of the new crown epidemic, some orders which are progressing according to the original plan were delayed, which ultimately affected the recognition of revenue.

For example, Lutheran environment said that the bidding and negotiation procedures for some orders planned to be obtained in the first half of the year affected by the epidemic situation were delayed, and the landing of new orders was affected to a certain extent. In addition, due to the fact that Lutheran environments river lake sludge business mostly came from Wuhan, the projects gradually resumed normal operation in April, and the resumption time was relatively late, which greatly affected the income in the first half of the year.

In addition, affected by the epidemic situation, the companys revenue decreased year on year also included: Tieke rail, lebtec, olaid, etc.

In addition to the expected year-on-year growth or decline in the third quarter, the revenue of Zhejiang Heidemann, Kewell, Ruilian new materials and Yuandong biological Co., Ltd. will change from - to +.

For example, in the first three quarters, Ruilian new material expects to achieve an operating revenue of 700-800 million yuan, with a year-on-year change of - 9.82% to 3.06%, and a net profit of 108-128 million yuan, with a year-on-year change of - 11.37% to 5.04%. The novel coronavirus epidemic will be affected by the new coronavirus epidemic in the first three quarters of this year, and some of the high intermediate profit products will be recognized in the fourth quarter after the shipment, resulting in a decrease in revenue and net profit compared to the same period last year. However, there is no significant adverse change in the performance of the first three quarters of 2020. And more companies are not afraid of the impact of the new crown epidemic, performance rose against the trend. For example, sirip, whose main product is signal chain analog chips, predicts that its revenue range from January to September this year will be 380 million yuan to 450 million yuan, with a year-on-year growth of 104.76% - 142.42%; the net profit range of parent company from January to September 2020 is expected to be 121 million yuan-166 million yuan, with a year-on-year growth of 200.23% - 311.24%. The main reason is that the demand of direct sales customers in the communication industry continues to rise, resulting in a substantial increase in the current sales scale, according to srip. Source: Science and technology innovation board daily editor: Wang Wenhua_ NF5982

For example, in the first three quarters, Ruilian new material expects to achieve an operating revenue of 700-800 million yuan, with a year-on-year change of - 9.82% to 3.06%, and a net profit of 108-128 million yuan, with a year-on-year change of - 11.37% to 5.04%. The novel coronavirus epidemic will be affected by the new coronavirus epidemic in the first three quarters of this year, and some of the high intermediate profit products will be recognized in the fourth quarter after the shipment, resulting in a decrease in revenue and net profit compared to the same period last year. However, there is no significant adverse change in the performance of the first three quarters of 2020.

And more companies are not afraid of the impact of the new crown epidemic, performance rose against the trend.

For example, sirip, whose main product is signal chain analog chips, predicts that its revenue range from January to September this year will be 380 million yuan to 450 million yuan, with a year-on-year growth of 104.76% - 142.42%; the net profit range of parent company from January to September 2020 is expected to be 121 million yuan-166 million yuan, with a year-on-year growth of 200.23% - 311.24%.

The main reason is that the demand of direct sales customers in the communication industry continues to rise, resulting in a substantial increase in the current sales scale, according to srip.